文献速递心律失常血脂与心血管预防

66至74岁无其他CHA2DS2-VASc危险因素房颤患者未抗凝的卒中风险评估

Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors.
PubMed 文献 · JAMA Cardiol · 2021-01-01

结果显示未抗凝患者总体1年卒中发生率为1.1%,且随年龄从66岁的0.7%增至74岁的1.7%,卒中风险与性别无显著关联。提示该组患者中较年长者抗凝可能获益更大。

要点

  • 66至74岁无其他CHA2DS2-VASc因素的房颤患者未抗凝时1年卒中发生率为1.1%。
  • 卒中风险随年龄增长而增加,66岁为0.7%,74岁为1.7%。
  • 卒中发生率与性别无显著关联,但该组患者中较年长者可能从抗凝中获益更多。

核心结论

  • 在无其他CHA2DS2-VASc危险因素的66至74岁房颤患者中,未抗凝治疗时卒中风险随年龄增长而增加。
  • 数据提示该组患者中较年长者抗凝治疗更可能获益,而较年轻者净临床获益可能较小。

研究设计与样本

  • 基于加拿大安大略省关联行政数据库的回顾性队列研究。
  • 排除长期护理机构居住、既往抗凝治疗、瓣膜病、心力衰竭、高血压、糖尿病、卒中和血管疾病者。

主要发现

  • 未抗凝治疗患者总体1年卒中发生率为1.1%(95%CI,1.0%-1.3%)。
  • 未抗凝治疗患者1年无卒中死亡发生率为8.1%(95%CI,7.7%-8.5%)。
  • 卒中发生率与性别无显著关联。
  • 估计1年卒中风险从66岁的0.7%(95%CI,0.5%-0.9%)增至74岁的1.7%(95%CI,1.3%-2.1%)。

关键数值与推荐

  • 未抗凝治疗患者1年卒中发生率:总体1.1%(95%CI,1.0%-1.3%)。
  • 估计1年卒中风险:66岁0.7%(95%CI,0.5%-0.9%),74岁1.7%(95%CI,1.3%-2.1%)。

临床怎么用

  • 对于66至74岁无其他CHA2DS2-VASc危险因素的房颤患者,评估抗凝决策时应考虑年龄相关的卒中风险差异。
  • 较年轻患者(如66岁附近)抗凝净临床获益可能较小,而较年长患者(如74岁附近)更可能获益。

局限性

  • 本研究为观察性回顾性队列研究,可能存在未测量混杂因素。
  • 卒中结局仅基于住院记录,可能低估未住院的轻型卒中。
  • 研究人群为加拿大安大略省居民,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are limited clinical trial data and discrepant recommendations regarding use of anticoagulation therapy in patients with atrial fibrillation (AF) aged 65 to 74 years without other stroke risk factors. OBJECTIVES: To evaluate the risk of stroke without anticoagulation therapy in men and women with AF aged 66 to 74 years without other CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65-74 years, female sex) risk factors and examine the association of stroke incidence with patient age. DESIGN, SETTING, AND PARTICIPANTS: A population-based retrospective cohort study was conducted using linked administrative databases. The population included 16 351 individuals aged 66 to 74 years who were newly diagnosed with AF in Ontario, Canada, between April 1, 2007, and March 31, 2017. Exclusion criteria included long-term care residence, prior anticoagulation therapy, valvular disease, heart failure, hypertension, diabetes, stroke, and vascular disease. The cumulative incidence function was used to estimate the 1-year incidence of stroke in patients who did not receive anticoagulation therapy. Fine-Gray regression was used to study the association of patient characteristics with stroke incidence and derive estimates of stroke risk at each age. Death was treated as a competing risk and patients were censored if they initiated anticoagulation therapy. Inverse probability of censoring weights was used to account for patient censoring. Data analysis was performed from May 26, 2019, to December 9, 2020. EXPOSURES: Atrial fibrillation and age. MAIN OUTCOMES AND MEASURES: Hospitalizations for stroke. RESULTS: Of the 16 351 individuals with AF (median [interquartile range] age, 70 [68-72] years), 8352 (51.1%) were men; 6314 individuals (38.6%) started anticoagulation therapy during follow-up. The overall 1-year stroke incidence among patients who did not receive anticoagulation therapy was 1.1% (95% CI, 1.0%-1.3%) and the incidence of death without stroke was 8.1% (95% CI, 7.7%-8.5%). The incidence of stroke was not significantly associated with sex. The estimated 1-year stroke risk increased with patient age from 66 years (0.7%; 95% CI, 0.5%-0.9%) to 74 years (1.7%; 95% CI, 1.3%-2.1%). CONCLUSIONS AND RELEVANCE: The risk of stroke more than doubled in this study as men and women with AF but no other CHA2DS2-VASc risk factors aged from 66 to 74 years. These data suggest that anticoagulation therapy is more likely to benefit older individuals within this group of patients, whereas younger individuals are less likely to gain net clinical benefit from anticoagulation therapy.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Abdel-Qadir H, Singh SM, Pang A, et al. Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors. JAMA Cardiol. 2021. PMID: 34009232. doi:10.1001/jamacardio.2021.1232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。